Cartrophen Vet (100mg sodium pentosan polysulfate / mL) is a leading treatment for arthritis (also known as degenerative joint disease or DJD) and related musculoskeletal disorders which acts on the underlying disease processes that result in pain and lameness.
Cartrophen Vet is a disease modifying osteoarthritis drug (DMOAD) and importantly, it helps maintain joint health, including preserving joint cartilage that is damaged by the arthritic process.
With 20% of dogs over one year of age suffering from arthritis (specifically osteoarthritis or OA) this is a common cause of pain and lameness (Hegemann et al., 2002).
With Cartrophen Vet showing effective treatment in over 80% of cases (Francis and Read, 1993; Cullis-Hill and Ghosh, 1994; Bouck et al, 1995; Read et al, 1996; Smith et al 2001) by way of disease modification, Cartrophen Vet represents the logical approach to the treatment of arthritis.
Cartrophen Vet (100mg sodium pentosan polysulfate / mL) and its concentrated form, Cartrophen Equine Forte (250mg sodium pentosan polysulfate / mL) are leading treatments for equine traumatic joint disease and equine arthritis (also referred to as DJD). Cartrophen has multiple sites of activity that modify the underlying processes of the disease and reduce the associated lameness and pain.
With 60% of lameness in the horse related to arthritis (Caron and Genovese, 2003), it is important to be vigilant for the signs of equine traumatic joint disease and address the underlying causes of the disease before they become established.
Francis DJ and Read RA (1993). Pentosan polysulphate as a treatment for osteoarthritis (degenerative joint disease) in dogs. Aust. Vet. Practit. 23(2):104 - 109
Bouck GR, Miller CW and Taves CL (1995). A comparison of surgical and medical treatment of fragmented coronoid process and osteochondritis dissecans of the canine elbow. V.C.O.T. 8: 177-183
Caron JP and Genovese RL (2003) Principles and practices of joint disease treatment. In M.W. Ross and S.J. Dyson (Ed.) Diagnostics and Management of Lameness in the Horse pp 746 -764. Elsevier Science, Philadelphia
Cullis-Hill D and Ghosh P (1994). Joint Convention of L’Ordre des. Medicins veterinaries du Quebec and the Canadian Veterinary Medical Association, Quebec City, Canada, July 6-9
Hegemann N, Kohn B, Brunnberg L, Schmidt MF (2002) Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders. Osteoarthritis Cart. 10, 714-721
Read RA, Cullis-Hill D and Jones MP (1996). Systemic use of pentosan polysulfate in the treatment of osteoarthritis. J.Small Anim Pract. 37: 108 – 114
Smith JG, Hannon RL, Brunnberg L, Gebski V, Cullis-HiII D (2001) A Randomised double blind comparator clinical study of the efficacy of sodium pentosan Polysulfate injection and carprofen capsules in arthritic dogs, Journal of the Osteoarthritis Research Society International, 9(b):S21-S22